1.Sureau, C, Guerra, B and Lanford, RE (1993) Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion. Journal of Virology 67, 366–372.
2.Rizzetto, M et al. (1988) Hepatitis delta virus infection: clinical and epidemiological aspects. In: Zuckerman, AJ (ed), Viral Hepatitis and Liver Disease, New York: Alan R. Liss, pp. 389–394.
3.Gerin, JL, Casey, JL and Purcell, RH (2002) Hepatitis delta virus. In: Hollinger, FB, Purcell, RH, Gerin, JL, Ganem, DE, Feinstone, FM (eds), Viral Hepatitis, United States: Lippincott Williams and Wilkins, pp. 169–192.
4.Taylor, JM (2006) Hepatitis delta virus. Virology 344, 71–76.
5.Taylor, JM (1996) Hepatitis delta virus and its replication. In Fields, BN, Knipe, DM, Howley, PM (eds), Fundamental Virology, 3rd Edn. Philadelphia: Lippincott-Raven Publishers, pp. 1235–1244.
6.Flores, R, Ruiz-Ruiz, S and Serra, P (2012) Viroids and hepatitis delta virus. Seminars in Liver Disease 32, 201–210.
7.Shirvani-Dastgerdi, E and Tacke, F (2015) Molecular interactions between hepatitis B virus and delta virus. World Journal of Virology 4, 36–41.
8.Casey, JL et al. (1996) Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. Journal of Infectious Diseases 174, 920–926.
9.Sagnelli, E et al. (1991) Interaction between HDV and HBV infection in HBsAg-chronic carriers. Infection 19, 155–158.
10.Stroffolini, T et al. (1992) Hepatitis B virus DNA in chronic HBsAg carriers: correlation with HBeAg/anti-HBe status, anti-HD and liver histology. Hepato-gastroenterology 39, 62–65.
11.Caredda, F et al. (1983) Prospective study of epidemic delta infection in drug addicts. Progress in Clinical and Biological Research 143, 245–250.
12.Smedile, A et al. (1982) Influence of delta infection on severity of hepatitis B. The Lancet 2, 945–947.
13.Rizzetto, M et al. (1983) Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Annals of Internal Medicine 98, 437–441.
14.Petruzziello, A (2018) Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma. The Open Virology Journal 12(Suppl.-1, M3) 26–32.
15.Petruzziello, A et al. (2017) Hepatitis C virus (HCV) genotypes distribution among hepatocellular carcinoma patients in Southern Italy: a three year retrospective study. Infectious Agents and Cancer 12, 52.
16.Bray, F et al. (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer 132, 1133–1145.
17.Ferlay, J et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 136, E359–E386.
18.Farci, P and Niro, GA (2012) Clinical features of hepatitis D. Seminars in Liver Disease 32, 228–236.
19.Buti, M et al. (2011) Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. Journal of Viral Hepatitis 18, 434–442.
20.Grabowski, J and Wedemeyer, H (2010) Hepatitis delta: immunopathogenesis and clinical challenges. Digestive Diseases 28, 133–138.
21.Ajiro, M and Zheng, ZM (2014) Oncogenes and RNA splicing of human tumor viruses. Emerging Microbes and Infection 3, e63.
22.Mesri, EA, Feitelson, MA and Munger, K (2014) Human viral oncogenesis: a cancer hallmarks analysis. Cell Host & Microbe 15, 266–282.
23.International Agency for Research on Cancer (2012) Vol 100B, 31–33.
24.International Agency for Research on Cancer (1994) Vol 59, 223–242.
25.Ghamari, S et al. (2013) Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients with unusual clinical pictures. Hepatitis Monthly 13, e6731.
26.Fattovich, G et al. (2000) Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 46, 420–426.
27.Cross, TJ et al. (2008) The increasing prevalence of hepatitis delta virus (HDV) infection in South London. Journal of Medical Virology 80, 277–282.
28.Uzunalimoğlu, O et al. (2001) Risk factors for hepatocellular carcinoma in Turkey. Digestive Diseases and Sciences 46, 1022–1028.
29.Değertekin, H, Yalçin, K and Yakut, M (2006) The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turkish Journal of Gastroenterology 17, 25–34.
30.Toukan, AU et al. (1987) The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan. Hepatology 7, 1340–1345.
31.Romeo, R et al. (2009) A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 136, 1629–1638.
32.Rosina, F et al. (1999) Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 117, 161–166.
33.Ji, J, Sundquist, K and Sundquist, J (2012) A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. Journal of the National Cancer Institute 104, 790–792.
34.Romeo, R et al. (2014) High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS ONE 9, e92062.
35.Tamura, I et al. (1993) Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. Journal of Gastroenterology and Hepatology 8, 433–436.
36.Huo, TI et al. (1996) Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. Journal of Hepatology 25, 439–444.
37.Amougou, MA et al. (2016) A prominent role of hepatitis D virus in liver cancers documented in Central Africa. BMC Infectious Diseases 16, 647.
38.Béguelin, C et al. (2017) Swiss HIV Cohort Study. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology 66, 297–303.
39.Alves, C, Branco, C and Cunha, C (2013) Hepatitis delta virus: a peculiar virus. Advances in Virology 2013, 560105.
40.Niro, GA et al. (2005) Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacology Therapy 22, 227–232.
41.Garripoli, A et al. (1994) Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 14, 154–157.
42.Yurdaydin, C et al. (2002) Famciclovir treatment of chronic delta hepatitis. Journal of Hepatology 37, 266–271.
43.Lau, DT et al. (1999) Lamivudine for chronic delta hepatitis. Hepatology 30, 546–549.
44.Wedemeyer, H et al. (2011) HIDIT study group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. The New England Journal of Medicine 364, 322–331.
45.Niro, GA, Rosina, F and Rizzetto, M (2005) Treatment of hepatitis D. Journal of Viral Hepatitis 12, 2–9.
46.Farci, P et al. (1994) Treatment of chronic hepatitis D with interferon alfa-2a. The New England Journal of Medicine 330, 88–94.
47.Niro, GA et al. (2006) Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44, 713–720.
48.Castelnau, C et al. (2006) Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 44, 728–735.
49.Erhardt, A et al. (2006) Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver International 26, 805–810.
50.Gheorghe, L et al. (2011) Weight-based dosing regimen of peg-interferon α−2b for chronic hepatitis delta: a multicenter Romanian trial. Journal of Gastrointestinal and Liver Diseases 20, 377–382.
51.Yurdaydin, C et al. (2008) Treatment of chronic delta hepatitis with lamivudine vs lamivudine+ interferon vs interferon. Journal of Viral Hepatitis 15, 314–321.
52.Wedemeyer, H, Yurdaydin, C and Caruntu, FA (2014) Pegylated-interferon-alpha2a plus tenofovir or placebo for the treatment of hepatitis delta. 49th Annual Meeting of the European Association for the Study of the Liver (EASL), London, United Kingdom. 9–13 April 2014.
53.Wranke, A et al. (2017) Antiviral treatment and liver-related complications in hepatitis delta. Hepatology 65, 414–425.
54.Meier, A et al. (2013) Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology 58, 31–42.
55.Zhong, G et al. (2013) Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. Journal of Virology 87, 7176–7184.
56.Ni, Y et al. (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070–1083.
57.Li, W and Urban, S (2016) Entry of hepatitis B and hepatitis D virus into hepatocytes: basic insights and clinical implications. Journal of Hepatology 64, S32–S40.
58.Schulze, A et al. (2010) Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. Journal of Virology 84, 1989–2000.
59.Bogomolov, P et al. (2016) Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. Journal of Hepatology 65, 490–498.
60.Bordier, BB et al. (2002) A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. Journal of Virology 76, 10465–10472.
61.Koh, C et al. (2015) Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. The Lancet Infectious Diseases 15, 1167–1174.
62.Kocisko, DA et al. (2006) Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrobial Agents Chemotherapy 50, 1034–1044.
63.Al-Mahtab, M, Bazinet, M and Vaillant, A (2016) Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS ONE 11, e0156667.
64.Guilhot, S et al. (1994) Expression of the hepatitis delta virus large and small antigens in transgenic mice. Journal of Virology 68, 1052–1058.
65.Negro, F et al. (1988) Chronic HDV (hepatitis delta virus) hepatitis. Intrahepatic expression of delta antigen, histologic activity and outcome of liver disease. Journal of Hepatology 6, 8–14.
66.Benekli, M et al. (2003) Signal transducer and activator of transcription proteins in leukemias. Blood 101, 2940–2954.
67.Niu, G et al. (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21, 7001–7010.
68.Park, CY et al. (2009) Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappa B signaling. Molecular Cell 28, 49–55.
69.Benegiamo, G et al. (2013) Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells. FEBS Letters 587, 1424–1428.
70.Dastgerdi, ES, Herbers, U and Tacke, F (2012) Molecular and clinical aspects of hepatitis D virus infections. World Journal of Virology 1, 71–78.
71.Zhang, Q et al. (2016) Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. Journal of Translational Medicine 14, 328.
72.McFarlane, BM et al. (1995) Autoimmune mechanisms in chronic hepatitis B and delta virus infections. European Journal of Gastroenterology and Hepatology 7, 615–621.
73.Nisini, R et al. (1997) Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles. Journal of Virology 71, 2241–2251.
74.Wedemeyer, H and Manns, MP (2010) Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nature Reviews Gastroenterology and Hepatology 7, 31–40.
75.Abbas, Z et al. (2015) Hepatitis D and hepatocellular carcinoma. World Journal of Hepatology 7, 777–786.
76.Radjef, N et al. (2004) Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. Journal of Virology 78, 2537–2544.
77.Nakano, T et al. (2001) Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. Journal of General Virology 82, 2183–2189.
78.Lee, CM et al. (1996) Characterization of a new genotype II hepatitis delta virus from Taiwan. Journal of Medical Virology 49, 145–154.
79.Niro, GA et al. (1997) The predominance of hepatitis delta virus genotype I among chronically infected Italian patients. Hepatology 25, 728–734.
80.Sy, BT et al. (2015) Identification of a natural intergenotypic recombinant hepatitis delta virus genotype 1 and 2 in Vietnamese HBsAg-positive patients. Journal of Viral Hepatitis 22, 55–63.